Entering text into the input field will update the search result below

INO & PWRM - Monday Morning Stock Highlights! from CRWEfinance.com

Jan. 10, 2011 10:43 AM ET
Lynnai profile picture
Lynnai's Blog
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.




Inovio Pharmaceuticals, Inc. (AMEX:INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper highlighting positive preclinical results from Inovio’s novel DNA vaccine targeting HIV Clade C viruses in the journal Vaccine. Clade C is the predominant HIV-1 strain infecting people in sub-Saharan Africa, India, and China, and there is a critical need for a vaccine targeted to these areas.

The study, conducted by Inovio scientists and their collaborators, is described in the published paper, entitled "High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation.” In this study, the vaccine induced strong antibody and T-cell immune responses in rhesus monkeys. Furthermore, the vaccinated monkeys displayed protective effects against a subsequent challenge with an infectious dose of SHIV virus (chimeric HIV/SIV virus) compared to the placebo control animals. These results further support the proof of concept for Inovio’s global DNA vaccine candidates, PENNVAX-G (vaccine against HIV Clades A, C, and D) and PENNVAX-GP (vaccine against HIV Clades A, B, and C) in a relevant preclinical model. PENNVAX-G is currently being tested in a 92-patient global Phase I clinical study (RV-262) conducted by the U.S. Military HIV Vaccine Research Program (MHRP). PENNVAX-GP is being developed using a multi-year $23.5 million NIAID HIV vaccine development contract awarded to Inovio.

Inovio recently announced interim immunogenicity and safety data from its Phase I clinical study of PENNVAX-B, a DNA vaccine for the prevention of HIV Clade B infection. PENNVAX-B achieved high vaccine-induced response rates and strong magnitude of T-cell immune responses in vaccinated subjects. Similar to reported results from a Phase I clinical study of Inovio’s therapeutic DNA vaccine for cervical cancer, the response rates and magnitude of responses achieved in this study were significantly higher than those seen previously with other DNA vaccine trials. Complete immunogenicity data as well as end-of-study safety data from the PENNVAX-B study are expected in 2Q 2011.

Inovio Pharmaceuticals, Inc. engages in the discovery, development, and delivery of DNA vaccines with a focus on cancers and infectious diseases. Its SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens, such as influenza. The company's proprietary electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company's clinical programs include trials for human papillomavirus/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus, and human immunodeficiency virus vaccines. It also advances preclinical research for seasonal/pandemic influenza vaccine. Inovio Pharmaceuticals' partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. on May 14, 2010. Inovio Pharmaceuticals was founded in 1983 and is headquartered in Blue Bell, Pennsylvania.


Power3 Medical Products, Inc. (OTC:PWRM)

Rozetta-Cell Life Sciences, Inc. is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. PWRM plans to effect the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into PWRM, with PWRM remaining as the surviving company. The acquisition of Rozetta-Cell is expected to be completed in February 2011.

"We are very excited to be finally ridding ourselves of litigation that has plagued us for several years now," stated Ira L. Goldknopf, President and Chief Scientific Officer of PWRM. "We have big plans for the future beginning with our upcoming acquisition of Rozetta-Cell and are about to enter a long and substantial growth phase marked by advances in our science and intellectual property. Given the imminent nature of many of these transactions and breakthroughs, we have decided, in consultation with the financiers of Rozetta-Cell, that the best course of action for Power3 is to settle many of these lawsuits so that we can focus our attention exclusively on the acquisition of Rozetta-Cell and the development of our combined businesses after the merger."


Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally. Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors. 

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). PWRM applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.

To learn more about PWRM visit: http://www.Power3Medical.com




Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.  Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.